Avadel files US antitrust claims against Jazz over Xyrem
MLex Summary: Avadel filed US antitrust counterclaims accusing Jazz Pharmaceuticals of abusing the Food and Drug Administration’s regulatory drug approval process by improperly listing a patent related to the drug Xyrem in...To view the full article, register now.
Already a subscriber? Click here to view full article